anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Data collection tools were applied to this group before the research. A training program consisting of three sessions was applied to the intervention group. Each training session lasted an average of 90-100 minutes. Various methods and techniques were used in the trainings.
In a 92-week carcinogenicity study in mice given pitavastatin, at the maximum tolerated dose of 75 mg/kg/day with systemic maximum exposures (AUC) 26 times the clinical maximum exposure at 4 mg daily, there was an absence of drug-related tumors. 

In a 92-week carcinogenicity study in rats given pitavastatin at 1, 5, 25 mg/kg/day by oral gavage there was a significant increase in the incidence of thyroid follicular cell tumors at 25 mg/kg/day, which represents 295 times human systemic exposures based on AUC at the 4 mg daily maximum human dose. 

In a 26-week transgenic mouse (Tg rasH2) carcinogenicity study where animals were given pitavastatin at 30, 75, and 150 mg/kg/day by oral gavage, no clinically significant tumors were observed. 

Pitavastatin was not mutagenic in the Ames test with Salmonella typhimurium and Escherichia coli with and without metabolic activation, the micronucleus test following a single administration in mice and multiple administrations in rats, the unscheduled DNA synthesis test in rats, and a Comet assay in mice. In the chromosomal aberration test, clastogenicity was observed at the highest doses tested, which also elicited high levels of cytotoxicity. 

Pitavastatin had no adverse effects on male and female rat fertility at oral doses of 10 and 30 mg/kg/day, respectively, at systemic exposures 56- and 354-times clinical exposure at 4 mg daily based on AUC. 

Pitavastatin treatment in rabbits resulted in mortality in males and females given 1 mg/kg/day (30-times clinical systemic exposure at 4 mg daily based on AUC) and higher during a fertility study. Although the cause of death was not determined, rabbits had gross signs of renal toxicity (kidneys whitened) indicative of possible ischemia. Lower doses (15-times human systemic exposure) did not show significant toxicity in adult males and females. However, decreased implantations, increased resorptions, and decreased viability of fetuses were observed.
PROAIR RESPICLICK inhalation powder is supplied as a white inhaler with a red cap, in a sealed foil pouch, one pouch per carton.

Store at room temperature (between 15°C and 25°C; 59°F and 77°F). Avoid exposure to extreme heat, cold, or humidity.

Keep out of reach of children.

PROAIR RESPICLICK inhaler has a dose counter. Patients should never try to alter the numbers for the dose counter. Discard the inhaler 13 months after opening the foil pouch, when the counter displays 0, or after the expiration date on the product, whichever comes first. The labeled amount of medication in each actuation cannot be assured after the counter displays 0, even though the inhaler is not completely empty and will continue to operate [see Dosage and Administration (2.4), Patient Counseling Information (17)].
The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The topical corticosteroids are intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene) bis(oxy)]-,(6α, 11β, 16α)-. It has the following structural formula:

C26H32F207 M.W. 494.54

Each gram of Fluocinonide Cream USP, 0.05% (Emulsified Base) contains: 0.5 mg fluocinonide in a water-washable aqueous emollient base of stearyl alcohol, cetyl alcohol, mineral oil, propylene glycol, sorbitan monostearate, polysorbate 60, citric acid (hydrous) and purified water.

Each gram of Fluocinonide Cream USP, 0.05% contains: 0.5 mg fluocinonide in a specially formulated cream base consisting of stearyl alcohol, polyethylene glycol 8000, propylene glycol, 1,2,6-hexanetriol and citric acid (hydrous). This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophilic properties.

In this formulation, the active ingredient is totally in solution.

Each gram of Fluocinonide Gel USP, 0.05% contains: 0.5 mg fluocinonide in a specifically formulated gel base consisting of purified water, propylene glycol, edetate disodium, carbomer 934P, and sodium hydroxide. Hydrochloric acid is added to adjust the pH. This clear, colorless thixotropic vehicle is greaseless, non-staining and completely water miscible.

In this formulation, the active ingredient is totally in solution.

Each gram of Fluocinonide Ointment USP, 0.05% contains: 0.5 mg fluocinonide in an ointment base consisting of white petrolatum, castor oil, and sorbitan sesquioleate. It provides the occlusive and emollient effects desirable in an ointment.

In this formulation, the active ingredient is totally in solution.
Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
Standardized cat hair extract is a sterile glycerinated injectable solution containing the extractables of dried, powdered cat hair, wash and dander and 0.5% NaCl, 0.08% Na2HPO4, 0.036% KH2PO4, water for injection and 0.4%, phenol as preservative in sterile containers. All extracts are aseptically filled. Standardized cat hair extract is to be administered by prick-puncture or intradermal routes when used for diagnostic purposes and administered subcutaneously when used for immunotherapy injections. 

The Bioequivalent Allergy Unit (BAU) nomenclature, now used for all Standardized Cat Extracts, replaces the previous Allergy Unit (AU) nomenclature for these products. Bioequivalent Allergy Units are based on quantitative intradermal skin test results and are intended to assure that the labeled unit of different allergenic extracts will correspond to the expected clinical response in sensitive patients. References labeled 10,000 BAU/mL can be diluted to one half million fold to produce an intradermal sum of erythema diameter response of 50 mm in highly puncture reactive subjects. 

In vitro assignment of BAU/mL to this product is based on radial immunodiffusion (RID) assay results according to guidelines established by the Center for Biologics Evaluation and Research (CBER) as indicated below.(5, 6)

Bioequivalent Allergy Units (BAU) are NOT interchangeable with Allergy Units (AU). Standardized Cat Hair extract labeled in BAU/mL are not interchangeable with standardized cat pelt extracts or with cat hair extracts labeled in AU/mL or with non-standardized cat hair extracts.

It has been recognized through investigation that the allergens responsible for Cat allergy are found in the pelt, hair, dander, saliva, serum and urine.(1) Saliva especially when deposited on and in combination with the hair, root hairs and skin can produce a significant allergic reaction. Repeated surface washing of the animal proved significant enough so that the wash was added to the whole of the raw material producing the cat allergenic extract.(2,3,4) However the amount of Fel d 1 varies widely from animal to animal so it is an advantage to use raw material with a known amount of the antigen. Nelco's raw material, supplied by Biopol Laboratory, is dried, powdered cat hair, wash and dander, labeled with the number of Fel d 1 units in each gram of dried material per container. The raw material is extracted with a 50%(v/v) glycerinated diluent containing glycerin and 0.5% NaCl, 0.08% Na2HPO4, 0.036% KH2PO4, WFI, and 0.4% phenol as a preservative. Although extracts from whole pelts of cats are similar in content of Fel d 1 to extracts prepared only from wash, hair and dander, pelt extracts may contain other non-Fel d 1 allergenic molecules.
The present application relates to an aspartic acid protease targeted recognition PET molecular probe and use, which pertain to the technical field of chemistry. The present application provides a molecular probe. In the molecular probe, one glycine is added between CBT and lysine to construct an intramolecular cyclization skeleton GPN. The extended self-assembly skeleton can improve the flexibility of the compound, thereby allowing CBT to more easily undergo a click condensation reaction with the intramolecular cysteine for intramolecular condensation cyclization and making the probe less affected by high concentrations of free cysteines, further promoting the condensation cyclization of the probe and the self-assembly of aggregates from the probe in tumors to achieve a lasting high-quality visualized tumor apoptosis level. The molecular probe has good selectivity for caspase-3 and has an ability for in-vitro specific monitoring of tumor cell apoptosis. Furthermore, the molecular probe shows a good ability for monitoring of immunotherapy-induced cell apoptosis in a tumor xenograft tumor model undergoing immunotherapy.
This will be a randomized pilot split-mouth clinical trial of patients with spaces ≥ 3mm distal to the maxillary canines in need of closure through sliding mechanics. The sample consists of adolescent patients regardless of Angle's molar malocclusion who are receiving comprehensive full fixed appliance orthodontic treatment. Preformed conjoint archwires half being GUMMETAL and the other half SS, will be utilized. Each patient will have one side of the maxilla randomly allocated into the SS or GUMMETAL treatment group. The study will follow a split-mouth design to reduce the confounding variables from patient to patient on space closure mechanics. The maxillary arch in each subject will be randomized into a SS side or GM side using a random number generator. Spaces will be measured at; T0 is initial records, T1 is initiation of space closure, T2 will be 4 weeks after the initiation of space closure, T3 is another 4 weeks of space closure evaluation and T4 will be the final evaluation of space closure after 4 weeks from T3, via 3D intraoral scans of maxillary arches. Space measurement and calculations will utilize 3Shape software to measure the distance of canine movement based off the distal surface. Sliding mechanics will be activated through NiTi coil springs from the maxillary canines to the maxillary molars. The force will be standardized to 150 gms and will be measured each visit. The same provider will activate the NiTi coil spring for retraction, along with data collection. Superimposition of scans will be utilized to assess outcome measures.
Because azithromycin is principally eliminated via the liver, caution should be exercised when azithromycin is administered to patients with impaired hepatic function. Due to the limited data in subjects with GFR <10 mL/min, caution should be exercised when prescribing azithromycin in these patients (see  CLINICAL PHARMACOLOGY, Special Populations ,  Renal Insufficiency). 

Azithromycin for Injection should be reconstituted and diluted as directed and administered as an intravenous infusion over not less than 60 minutes (see  DOSAGE AND ADMINISTRATION). 

Local IV site reactions have been reported with the intravenous administration of azithromycin. The incidence and severity of these reactions were the same when 500 mg azithromycin were given over 1 hour (2 mg/mL as 250 mL infusion) or over 3 hours (1 mg/mL as 500 mL infusion) (see  ADVERSE REACTIONS). All volunteers who received infusate concentrations above 2 mg/mL experienced local IV site reactions and, therefore, higher concentrations should be avoided. 

Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy. 

Prescribing Azithromycin for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The invention discloses a Chinese giant salamander viral hemorrhagic disease cell culture-based inactivated vaccine, its preparation method and an application thereof. The preparation method comprises the following steps of: A, EPC cell thawing; B, EPC cell culture used for amplification of Chinese giant salamander iridovirus; C, GSIV virus amplification: an infected virus-suspended liquid is added when a bottle bottom is filled with EPC passage cells; D, GSIV virus harvesting: the virus is continuously cultured to obtain an amplified virus liquid used for subsequent titer experiment and inactivated vaccine; E, virus titer testing: the virus is titered as the titer of the inactivated vaccine; F, GSIV virus inactivation: a stock solution of the Chinese giant salamander iridovirus inactivated vaccine is obtained and stored in a freezer; and G, inactivation of viral vaccine: the inactivated vaccine is diluted by the use of fish normal saline to obtain the Chinese giant salamander cell cuture-based inactivated vaccine. The invention also relates to an application of the inactivated vaccine in the preparation of drugs for curing or preventing Chinese giant salamander viral hemorrhagic disease. The preparation method is simple and convenient to operate. By the use of the inactivated vaccine, the virus is thoroughly inactivated. The inactivated vaccine has high safety. The protection rate of immersion immunization reaches 73% and that of injection immunization reaches 82%.
This study is designed to explain the unexpected effects of obesity on NO bioavailability in the airways of asthmatics: Specifically, that obesity induces systemic oxidative stress in part through increased production of reactive oxygen species (ROS) in adipose tissue and, in parallel (or as a consequence), increased systemic levels of tumor necrosis factor (TNF-α)and 8-isoprostanes. Furthermore, it creates an imbalance in the regulation of protective anti-oxidant thiol/disulfide pairs such as glutathione/glutathione disulfide. We hypothesize that in asthmatics, the lung is a target-organ of this obesity-related systemic oxidative stress. This is manifested as increased oxidation of airway NO into nitrate and reactive nitrogen species (RNS) including peroxynitrate and nitrotyrosine, thereby reducing NO bioavailability and exhaled NO levels. NO has many key physiological properties including bronchodilation, anti-tumoral/bactericidal activity, and anti-inflammatory and anti-oxidative activity. Thus, reduced NO bioavailability in obese asthmatics could favor increased bronchoconstriction and impair the lung's ability to respond to further oxidative or inflammatory challenges. Therefore, we hypothesize that: 1) obesity causes redox stress in the airway, which in turn decreases the bioavailability of NO by shunting it into RNS, 2) that weight loss will decrease systemic oxidative stress and thereby increase NO bioavailability due to decreased oxidation into RNS, and 3) that by decreasing systemic oxidative stress, weight loss will reduce bronchial hyper-reactivity.
AIMS OF THE STUDY: This pilot study aims to enhance understanding by examining parents' specific views on the requirements, content and objectives of case management and advanced care coordination for children with rare diseases during childhood. The findings of this study are expected to offer valuable insights and recommendations for existing and future initiatives in clinical practice and research, with the goal of improving the comprehensive, child-centred and family-orientated approach to case management.
METHODS: This pilot study is part of an ongoing prospective study (SPACE), involving parents and families from various networks in Switzerland. Participants were parents recruited from the Children with Rare Diseases (KMSK) network consisting of families with children with rare diseases. The survey questionnaire covered demographic information; expectations and perceived need for case management; assessment of their quality of life and their child's suffering; and evaluation of interprofessional and interdisciplinary communication. Qualitative data from free-response answers were analysed using Mayring's content analysis and descriptive statistics were used to analyse quantitative data from Likert-scale questions.
RESULTS: The study included 108 respondent families from among the 775 in the KMSK, a 14% response rate. The age of their children ranged from 0.4 to 24 years (mean: 8) and their level of suffering in the past six months varied, with 31.5% indicating intense or very intense suffering. In terms of case management, 15.8% of families reported access while 32.4% expressed a need but did not have access to it. The study identified three categories of parental expectations regarding case management, emphasising the importance of interprofessional collaboration, effective communication and comprehensive support.
CONCLUSIONS: The findings shed light on the high need for case management support with a current undersupply in Switzerland and an association with reduced parental quality of life, highlighting the necessity for diverse support and assistance to effectively manage the challenges faced by families with children with rare diseases.
The invention discloses a traditional Chinese medicine composition treating kidney-yang-insufficiency blood-stasis type lumbar muscle strain and a preparation method thereof. The traditional Chinese medicine composition comprises campanumoea lancifolia, bark of aphananthe aspera, leaf of manynerve bauhinia, all-grass of bulley herminium, byttneria aspera, euonymus subsessilis sprague, euonymus giraldii Loes., myrica esculenta Buch.-Ham., begonia limprichtii Irmsch., gongronema nepalense (Wall.) Decne., humata repens (L. F.) Didls, pilea lomatogramma Hand.- Mazz, decaspermum esquirolii (Levl.)Chang et Miau, and visum liquidambaricolum Ha-yata. The preparation method comprises: according to different properties of the medicines, performing extraction on uonymus subsessilis sprague, myrica esculenta Buch.-Ham., campanumoea lancifolia, byttneria aspera and begonia limprichtii Irmsch. by using ethanol, performing water-decoction extraction on gongronema nepalense (Wall.) Decne., euonymus giraldii Loes., decaspermum esquirolii (Levl.)Chang et Miau, humata repens (L. F.) Didls, visum liquidambaricolum Ha-yata, bark of aphananthe aspera, leaf of manynerve bauhinia, all-grass of bulley herminium and pilea lomatogramma Hand.- Mazz, performing filtering on all medicine powder residue, so as to obtain an extraction liquid, preparing a thick paste from the extraction liquid, extracting by using ethyl acetate, recovering ethyl acetate, performing freeze drying, crushing, and adding auxiliary materials to prepare an oral preparation. The traditional Chinese medicine composition treating kidney-yang-insufficiency blood-stasis type lumbar muscle strain is reasonable in formula, lasting in drug effect, substantial in curative effect, short in treatment course, fast in effectiveness and free of side effect.
BACKGROUND: Iopamidol is a non-ionic, water-soluble iodine contrast agent that is considered safe for intravenous or intra-arterial administration and is widely used both in the general population and in patients undergoing oncological treatment. While adverse reactions to iopamidol have been documented, to date, no pulmonary and gastric hemorrhages induced by iopamidol have been reported in oncology patients. We report the first case of this complication.
CASE PRESENTATION: We report the case of a 60-year-old woman with marginal zone lymphoma who was receiving antineoplastic therapy. As part of the investigation for the condition, she underwent chest enhancement CT with iopamidol. Shortly thereafter(within five minutes), she experienced hemoptysis and hematemesis. She was intubated and admitted to the intensive care unit. Pre- and post-contrast images demonstrated the course of the hemorrhage. Flexible bronchoscopy and gastroscopy on the following day showed no active bleeding, and the patient recovered completely after antiallergy treatment. We speculate that contrast-induced hypersensitivity was the most likely cause of the transient pulmonary and gastric bleeding.
CONCLUSION: Although rare, the complications of iopamidol, which may cause allergic reactions in the lungs and stomach, should be considered.
The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
Participants in the study were given group otago exercises for 4 weeks, face to face, once a week for 30 minutes. They were also given brochures containing otago exercises twice a week and followed up remotely. They were asked to walk normally for 30 minutes, 2 days a week. Then they entered a 4-week cleansing period.
The patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set.
The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.